Arvinas, Inc., a clinical-stage biotechnology company, engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. The company engineers proteolysis targeting chimeras (PROTAC) targeted protein degraders that are designed to harness the body's own natural protein disposal system to degrade and remove disease-causing proteins. Its product pipeline includes Bavdegalutamide and ARV-766, investigational orally bioavailable PROTAC protein degraders for the treatment of men with metastatic castration-resistant prostate cancer, which are in Phase 1/2 clinical trials; and ARV-471, an orally bioavailable estrogen receptor degrading PROTAC targeted protein degrader for the treatment of patients with locally advanced or metastatic estrogen receptor+/human epidermal growth factor receptor 2-breast cancer, which is Phase 3 clinical trial. Arvinas, Inc. has collaborations with Pfizer Inc., Genentech, Inc., F. Hoffman-La Roche Ltd., Carrick Therapeutics Limited, and Bayer AG. The company was founded in 2013 and is based in New Haven, Connecticut.
| 26.57 | |
| 25.57 | |
| - | |
| 26.67 | |
| 25.25 | |
| 13.57-53.08 | |
| 1 824 M | |
| 68 648 K | |
| 93 300 K | |
| -0.49 | |
| 1.971 |
No long-term obligations. The minimum period is one month only. No wait. You get an API key with instructions in a few seconds right after subscription.
As every investor would know, not every swing hits the sweet spot. But really bad investments should be rare. So take a moment to sympathize with the long term shareholders of Arvinas, Inc. (NASDAQ:AR...
We recently compiled a list of the 10 Best Small-Cap Healthcare Stocks To Buy Now.In this article, we are going to take a look at where Arvinas, Inc. (NASDAQ:ARVN) stands against the other small-cap h...
Our 24/7 support would be happy to assist you via chat or email:
support@eodhistoricaldata.comVisit also:
